• Wix Facebook page
  • Wix Twitter page
  • Wix Google+ page

Germantown Company Wins Approval for Revolutionary Glucose Monitoring System



Germantown-based Senseonics Holdings, Inc. announced the U.S. Food and Drug Administration has approved its Premarket Approval application to market the company's Eversense Continuous Glucose Monitoring System to people with diabetes in the United States. The system is the first and only Continuous Glucose Monitoring System to feature an implantable glucose sensor and provide long-term continuous monitoring for up to three months.

The technology relies on a small device that’s implanted under the skin of the upper arm. A transmitter is stuck to the skin over the spot where the implant is located, which relies on fluorescence to determine the readings measured by the implant. The transmitter then sends the data, via Bluetooth, to a paired smartphone or smartwatch, which keeps tabs on the patient’s historical blood glucose trends.